Annual Reports in Medicinal Chemistry book cover

Annual Reports in Medicinal Chemistry

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.

Audience
medicinal, pharmaceutical, and organic chemists

Paperback, 736 Pages

Published: October 2009

Imprint: Academic Press

ISBN: 978-0-12-374766-2

Contents

  • 1 Recent advances in the discovery of GSK-3 inhibitors and a

    perspective on their utility for the treatment of Alzheimer’s

    disease

    Robert G. Gentles, Shuanghua Hu,

    and. Gene Dubowchik

    2 Advances in the Development of Nitric Oxide Synthase Inhibitors

    Shawn Maddaford, Subhash

    Annendi, Jailall Remnauth, and

    Suman Rakhit

    3 Small Molecule Protein–Protein Interaction Inhibitors as

    Therapeutic Agents for Neurodegenerative Diseases: Current

    Progress and Future Hurdles

    Simon Haydar and Warren Hirst

    4 Case History: Chantix (varenicline tartrate) a Nicotinic Partial

    Agonist Aid to Smoking Cessation

    Jotham W. Coe, Hans Rollema and

    Brian T. O’Neill

    5 Case History on Tekturna® /Rasilez® (Aliskiren), a Highly

    Efficacious Direct Oral Renin Inhibitor as a New Therapy for

    Hypertension

    Juergen Maibaum and David Feldman

    6 Advances in Vasopressin Receptor Agonists and Antagonists Thomas Ryckmans

    7 The Emergence of GPR119 Agonists as Anti-diabetic Agents Robert Jones

    8 Non-peptide Ligands for the Gonadotropin Receptors Nicole van Straten, Marco Timmers

    9 Recent Advances in Coagulation Serine Protease Inhibitors

    Mimi Quan and Joanne Smallheer

    10 Advances in the Discovery of Anti-Inflammatory FMS Inhibitors Mark Player and Carl Manthey

    11 Recent Advances in the Discovery of CB2 Selective Agonists Jayant Thatte, Sangdon Han, and Rob Jones

    12 Advances in the Discovery of Small Molecule JAK3 Inhibitors Stephen Wrobleski

    13 Recent Advances in Adenosine Receptor (AR) Ligands in

    Pulmonary Diseases

    Jeff Zablocki and Rao Kalla

    14 Recent Progress in the Development of Small Molecule Inhibitors

    of Insulin-like Growth Factor Receptor (IGF-1R) Kinase Dinesh Vyas and Mark Wittman

    15 Case History: Discovery of Ixabepilone (IXEMPRA[TM]), a First-inclass

    Epothilone Analogue for Treatment of Metastatic Breast Cancer

    Robert M. Borzilleri and Gregory D.

    16 Hedgehog Signaling Pathway Inhibitors as Cancer Therapeutics Stefan Peuker and Karen Miller-Moslin

    17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-

    3-Kinases (PI3Ks)

    John M. Nuss, Amy Lew Tsuhako

    and Neel K. Anand Exelixis

    18 Anti-infective Activity of Artemisinin and its Semi-synthetic

    Derivatives John G. D'Angelo

    19 Recent Advances in the Inhibition of Bacterial Type II

    Topoisomerases

    Greg Bisacchi & Jacques Dumas

    20 Progress Towards the Discovery and Development of Specifically

    Targeted Inhibitors of Hepatitis C Virus

    Nicholas A. Meanwell John F.

    Kadow and Paul M. Scol

    21 Inhibitors of Nuclear Hormone Receptor/Steroid Receptor

    Coactivator Interactions

    Terry Moore, John Katzenellenbogen

    22 Safety Testing of Drug Metabolites Tom Thompson

    23 A Path to Innovation: Gene Knockouts Model New Drug Action Brian Zambrowicz

    24 Discovery of Novel Positron Emission Tomography (PET) Tracers Dennis McCarthy

    25 The Use of Isotopically Labeled Compounds in Drug Discovery (Chad) Charles S. Elmore

    26 Mechanism based inhibition of CYP3A4 and other cytochromes P450 Bernard Murray

    27 Nonclinical Toxicogenomics in the Pharmaceutical Environment Bruce D. Car

    28 To Market, To Market 2008 Shridhar Hegde and Michelle Schmidt

     

Advertisement

advert image